DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 20-297/S-029

GlaxoSmithKline
Attention: Catherine K. Clark
Director, US Regulatory Affairs
One Franklin Plaza
200 N. 16th Street
Philadelphia, PA 19102

Dear Ms. Clark:

Please refer to your supplemental new drug application dated April 22, 2008, submitted under section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act for COREG (carvedilol) 3.125 mg, 6.25 mg, 12.5 mg, and 25 mg Tablets.

We acknowledge receipt of your submissions dated December 22, 2008, and March 10, 2009, as well as your e-mail dated June 23, 2009.

This supplemental new drug application provides for labeling revised as follows:

1. In **HIGHLIGHTS/RECENT MAJOR CHANGES,** in accordance with 201.57(a)(5) and subsequent to the expiration of the one-year inclusion period, the Warnings and Precautions listing has been removed.

2. In **HIGHLIGHTS/CONTRAINDICATIONS**, the seventh bullet has been changed from:

   Hypersensitivity to carvedilol

   To:

   History of serious hypersensitivity reaction (e.g. Stevens-Johnson syndrome, anaphylactic reaction, angioedema) to any component of this medication or other medications containing carvedilol

3. In **CONTRAINDICATIONS**, the seventh bullet has been modified from:

   Patients with a history of a serious hypersensitivity reaction to carvedilol

   To:

   Patients with a history of serious hypersensitivity reaction (e.g. Stevens-Johnson syndrome, anaphylactic reaction, angioedema) to any component of this medication or other medications containing carvedilol.

4. In the ADVERSE REACTIONS/**Post Marketing Experience** section, the following sentence has been added:

Rare reports of hypersensitivity reactions (e.g., anaphylactic reaction, angioedema, and urticaria) have been received for COREG and COREG CR, including cases occurring after the initiation of COREG CR in patients previously treated with COREG.

5. In the **PATIENT INFORMATION** leaflet under **What are the possible side effects of COREG?**, the following has been added as the eighth bullet:

   - Rare but serious allergic reactions (including hives or swelling of the face, lips, tongue and/or throat that may cause difficulty breathing or swallowing) have happened in patients who were on COREG. These reactions can be life-threatening.

We have completed our review of this application, as amended, and it is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, please submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format as described at http://www.fda.gov/oc/datacoucil/spl.html that is identical to the enclosed labeling (text for the package insert). Upon receipt, we will transmit that version to the National Library of Medicine for public dissemination. For administrative purposes, please designate this submission, "**SPL for approved NDA 20-297/S-029**."

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
Suite 12B05
5600 Fishers Lane
Rockville, MD 20857

If you have any questions, please call:

Lori Anne Wachter, RN, BSN
Regulatory Project Manager
(301) 796 3975

Sincerely,
{See appended electronic signature page}
Norman Stockbridge, M.D., Ph.D.
Director
Division of Cardiovascular and Renal Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

Enclosure: agreed-upon labeling text

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Norman Stockbridge

6/23/2009 04:04:49 PM